John Reynolds

30PUBLICATIONS
118CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Nanotoxicology, health and safetyMedical infection agents (incl. prions)Instruments and techniquesRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Oct 19, 2026
A randomized phase 2 study combining midostaurin, low-dose cytarabine and venetoclax in newly diagnosed AML ≥60 years.

|Jan 15, 2026
A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation.

Joanne Lay Cheng Tan, Tiffany Khong, Yu Jin Kim

|Oct 17, 2025
Measurable residual disease intervention in AML: a new therapeutic horizon.

Andrew H Wei, Harry J Iland, Courtney D DiNardo

|Jul 29, 2025
Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML.

Rithin Nedumannil, Michael Ashby, James Rowland

|Jan 28, 2025
ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL.

Harry J Iland, John Reynolds, Alan V Boddy

|Jan 18, 2025
Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT).

Chong Chyn Chua, Sun Loo, Chun Yew Fong

Pageof 5

Frequent Collaborators

9 joint publications

Andrew Wei

5 joint publications

Ing Soo Tiong

4 joint publications

Harry J Iland

4 joint publications

Natasha S Anstee